Your Navigation:PCAR > Abstract
Search pcar
Pharmaceutical Care and Research: 2019; 19(1):74-76
DOI: 10.5428/pcar20190118
Pharmacists involvement in anticoagulant treatment of a patient with atrial fibrillation complicated with chronic kidney disease
1. YANG Jinyan(a
2. JIA Jinsheng(a
Welcome to PCAR! You are the number 410 reader of this article!
Please cite this article as:
YANG Jinyan,JIA Jinsheng,. Pharmacists involvement in anticoagulant treatment of a patient with atrial fibrillation complicated with chronic kidney disease[J]. Pharmaceutical Care and Research / yao xue fu wu yu yan jiu. 2019; 19(1): 74-76.
1. Providência R,Marijon E,Boveda S,et al.Meta-analysis of the influence of chronic kidney disease on the risk of thromboembolism among patients with nonvalvular atrial fibrillation[J].Am J Cardiol,2014,114(4):646-653.
2. Friberg L,Benson L,Lip G Y.Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study[J].Eur Heart J,2015,36(5):297-306.
3. January C T,Wann L S,Alpert J S,et al.2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society[J].Circulation,2014,130(23):e199-e267.
4. Bautista J,Bella A,Chaudhari A,et al.Advanced chronic kidney disease in non-valvular atrial fibrillation: extending the utility of R2CHADS2 to patients with advanced renal failure[J].Clin Kidney J,2015,8(2):226-231.
5. Schwartzenberg S,Lev E I,Sagie A,et al.The quandary of oral anticoagulation in patients with atrial fibrillation and chronic kidney disease[J].Am J Cardiol,2016,117(3):477-482.
6. MA Wenfang,LIANG Yan.Bleeding risk scores for anticoagulated patients with atrial fibrillation[J].Adv Cardiovasc Dis,2017,38(6):639-643.In Chinese with English abstract.
7. Kirchhof P,Benussi S,Kotecha D,et al.2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J].Eur J Cardiothorac Surg,2016,50(5):e1-e88
8. Olesen J B,Lip G Y,Kamper A L,et al.Stroke and bleeding in atrial fibrillation with chronic kidney disease[J].N Engl J Med,2012,367(7):625-635.
9. Sakaan S A,Hudson J Q,Oliphant C S,et al.Evaluation of warfarin dose requirements in patients with chronic kidney disease and end-stage renal disease[J].Pharmacotherapy,2014,34(7):695-702.
10. Agewall S,Cattaneo M,Collet J P,et al.Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy[J].Eur Heart J,2013,34(23):1708-1713,1713a-1713b.
11. Naganuma M,Shiga T,Nishikata K,et al.Role of desethylamiodarone in the anticoagulan effect of concurrent amiodarone and warfarin therapy[J].J Cardiovasc Pharmacol Ther,2001,6(4):363-367.
《药学服务与研究》杂志社 All Rights Reserved 网站备案号:鲁B2-20061008
·地址:上海市杨浦区长海路168号18号楼东三楼 邮政编码:200433
·联系电话(传真):86-21-65519829, 021-31162330